GARFIELD-VTE

  • Research type

    Research Study

  • Full title

    Global Anticoagulant Registry in the FIELD observing treatment and outcomes in patients with treated acute Venous Thromboembolic Events in the real world

  • IRAS ID

    155886

  • Contact name

    Peter MacCallum

  • Contact email

    p.k.maccallum@qmul.ac.uk

  • Sponsor organisation

    Thrombosis Research Institute

  • Clinicaltrials.gov Identifier

    NCT02155491, ClinicalTrials.gov Identifier (NCT number); 2013-004758-55, European Clinical Trials Database (EudraCT) number

  • Research summary

    Venous thromboembolism (VTE) is an important global patient safety issue. It is a common and increasing cause of morbidity and mortality with early and long-term management required to prevent acute and long-term chronic complications, such as onset of pulmonary embolism (PE) in patients presenting with deep vein thrombosis (DVT), recurrent VTE, post thrombotic syndrome (PTS) and chronic thromboembolic pulmonary hypertension (CTEPH).

    In consideration of the changing clinical landscape with the introduction of new oral anticoagulants, there is a definite need to observe the developments related to managing VTE around the world and gather data in order to understand the quality of treatment for patients and its impact on clinical outcomes.

    GARFIELD-VTE is global, prospective, observational, multi-centre VTE registry to be conducted in sequential cohorts, in order to observe temporal trends in management of VTE.

    A minimum of 2 cohorts will be recruited. Recruitment into the second (or subsequent cohorts) will commence when recruitment is completed into the first or previous cohort. It is estimated that each cohort will take approximately 9 months to recruit. Potential patients must be assessed for eligibility within 30 days of their acute VTE diagnosis.

    Cohort One
    5000 consecutive unselected patients treated for acute VTE and followed prospectively for a minimum of 36 months.

    Cohort Two
    A further 5000 consecutive unselected patients treated for acute VTE and followed prospectively for a minimum of 36 months.

  • REC name

    London - City & East Research Ethics Committee

  • REC reference

    14/LO/1350

  • Date of REC Opinion

    21 Jul 2014

  • REC opinion

    Favourable Opinion